OPDIVO® (nivolumab)
WEBAlone or in combination with other therapies, OPDIVO is approved by the FDA to be a first treatment option for many types of cancer. Talk to your healthcare provider to find out if OPDIVO or an OPDIVO‑based combination is right for you.
How This Treatment Works | OPDIVO® (nivolumab)
WEBLearn how OPDIVO® (nivolumab) alone and OPDIVO® + YERVOY® (ipilimumab) in combination work with your immune system to fight cancer. Ask your doctor if these immunotherapies may work for you. Access treatment information for your cancer type. Please see Indication and Important Safety Information.
Advanced PD-L1 Positive NSCLC | Clinical Trial Results |OPDIVO ...
WEBSee how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with advanced non-small cell lung cancer that tested positive for PD-L1 . Please see Indication and Important Safety Information.
Clinical trial results for - OPDIVO
WEBSee how OPDIVO® (nivolumab) performed in a clinical trial as a treatment for certain adults with previously treated advanced bladder or urinary tract cancer, or urothelial carcinoma. Please see Indication and Important Safety Information.
Financial Information: Cost, Access & Affordability - OPDIVO
WEBYou should use an effective method of birth control during your treatment and for 5 months after the last dose of OPDIVO or YERVOY. Talk to your healthcare provider about birth control methods that you can use during this time.
Patient and Caregiver Stories | OPDIVO® (nivolumab)
WEBWatch videos of real OPDIVO® (nivolumab) patients and caregivers. Learn more about patients' diagnoses and treatment experiences. Please see Indication and Important Safety Information.
Advanced Kidney Cancer | Clinical Trial Results - OPDIVO
WEBIn a clinical trial of 651 people with previously untreated advanced kidney cancer that had spread, 323 people were given OPDIVO + CABOMETYX and 328 people were given SUTENT ® (sunitinib malate), a standard treatment.
Advanced HCC | Clinical Trial Results - OPDIVO
WEBSee how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as a treatment for people with liver cancer (hepatocellular carcinoma) previously treated with sorafenib. Please see Indication and Important Safety Information.
OPDIVO ® with You
WEBSign up for OPDIVO with You, a support program that offers helpful information if you are about to start or are currently on OPDIVO® (nivolumab) or an OPDIVO®-based combination. Please see Indication and Important Safety Information.
WEBOPDIVO + YERVOY is approved as a first treatment for adults: Who have lung cancer that has spread to other parts of the body (metastatic) AND Whose tumors are positive for PD-L1 but do not have an abnormal EGFR or ALK gene.